WhaleCreep

Which hedge funds own VRNA? VERONA PHARMA PLC, Q2 2026 13F holders

0 tracked hedge funds disclosed a position in VRNA (VERONA PHARMA PLC) in their Q2 2026 13F filings, worth $0 in total.

0
Holders
0
New this quarter
0
Exited this quarter
$0
Combined value
–
Share of managers holding

Holders, Q2 2026

0 rows

Ownership over time

By quarter
QuarterHoldersManagers filingShare holdingCombined value
Q4 20250710.0%$0
Q3 20257739.6%$857m
Q2 202587311.0%$474m
Q1 202587311.0%$369m
Q4 20246748.1%$326m
Q3 20244735.5%$300m
Q2 20244735.5%$163m
Q1 20243734.1%$144m
Q4 20234735.5%$184m
Q3 20233734.1%$126m
Q2 20233734.1%$164m
Q1 20233734.1%$180m
Q4 20223734.1%$178m
Q3 20223744.1%$67.8m
Q2 20223744.1%$23.6m
Q1 20221741.4%$25.4m
Q4 20211741.4%$34.3m
Q3 20211711.4%$27.9m
Q2 20211711.4%$33.4m
Q1 20211701.4%$42.6m
Q4 20202712.8%$32.0m
Q3 20201681.5%$31.8m
Q2 20201681.5%$100k
Q1 20200680.0%$0
Q4 20191671.5%$72.0k
Q3 20190600.0%$0
Q2 20191601.7%$53.0k
Q1 20191601.7%$76.0k

Who discovered VRNA first?

Earliest meaningful positions among the 13 tracked managers seen opening VRNA since Q1 2019.

3 rows
RA Capital Management, L.P.Q3 20200.6%3.3%18Exited by Q1 2025+396%
Maverick Capital LtdQ4 20230.7%2.6%7Exited by Q3 2025+217%
Duquesne Family Office LLCQ3 20240.7%2.7%5Exited by Q4 2025+147%

Stock since is the split-adjusted change in the quarter-end price, excluding dividends, from the first reported quarter: the price the 13F filings themselves imply (value ÷ shares), blank across any gap that cannot be accounted for. It describes the stock, not the return any manager earned.